ImmunityBio, Inc. — fact timeline

ImmunityBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by our stockholders based on the following results of voting: Votes “For” Votes “Against” Abstentions “Broker Non-Votes” 882,420,139 1,675,960 1,070,960 —”

ImmunityBio, Inc. shareholders approved Election of Nine Directors at the 2026-06-09 meeting.

“1. Election of Nine Directors. The following nominees were re-elected by the holders of our Common Stock to serve as directors for a one year term expiring at the 2027 annual meeting of stockholders based on the following results of voting. Each director's term continues until the election and qualification of his or her successor, or until his or her earlier retirement, resignation, disqualification, removal, or death. Nominee Votes “For” Votes “Withheld” “Broker Non-Votes” Patrick Soon-Shiong, M.D. 714,631,732 19,014,153 151,521,174 Cheryl L. Cohen 731,554,649 2,091,236 151,521,174 Richard Adcock 731,960,821 1,685,064 151,521,174 Michael D. Blaszyk 722,575,150 11,070,735 151,521,174 Wesley Clark 729,527,285 4,118,600 151,521,174 Linda Maxwell, M.D. 717,976,024 15,669,861 151,521,174 Christobel Selecky 722,387,537 11,258,348 151,521,174 Barry J. Simon, M.D. 731,770,436 1,875,449 151,521,174 Bruce Wendel 732,149,734 1,496,151 151,521,174”

ImmunityBio, Inc. entered into Exclusive Development and Supply Agreement with Japan BCG Laboratory valued at No payment due prior to FDA approval; minimum 2 batches per year after approval (effective 2026-05-14).

“On May 14, 2026, ImmunityBio, Inc., a Delaware corporation (“ImmunityBio” or the “Company”), entered into an exclusive development and supply agreement (the “Agreement”) with Japan BCG Laboratory, a Japanese corporation (“JBL”).”

ImmunityBio, Inc. reported the three months ended March 31, 2026 results: revenue $44.2 million.

“9 – Financial Statements and Exhibits. --- EX-99.1 (EX-99.1) --- ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million • Q1 2026 Revenue Growth with Continued Strong”

ImmunityBio, Inc. reported the fiscal quarter ending March 31, 2026 results: revenue approximately $44.2 million.

“ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026”

ImmunityBio, Inc. incurred debt of $75.0 million with Infinity SA LLC, as collateral agent and administrative agent for the Purchasers at tiered range of 5.625% to 12.50%.

“(the “Company”) entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”) by and among the Company, the guarantors party thereto, the purchasers party thereto (the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Agent”), which amends that certain Revenue Interest Purchase Agreement dated as of December 29, 2023, by and among the Company, the Purchasers and the Agent (as amended, modified and supplemented prior to the date of the Amendment, the “RIPA”).”

ImmunityBio, Inc. amended Convertible Note Amendment with Nant Capital, LLC (effective 2026-01-23).

“On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and among the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.”

ImmunityBio, Inc. amended Amendment No. 1 with Jefferies LLC valued at $459,972,480 (effective 2025-12-23).

“On December 23, 2025, ImmunityBio, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment to Sale Agreement”) to the Open Market Sale Agreement SM dated April 30, 2021, (the “Sale Agreement”) with Jefferies LLC (the “Agent”) relating to the sale and issuance of shares of its common stock, par value $0.0001 per share (the “Shares”), from time to time through an “at the market” offering program under which the Agent acts as the Company’s sales agent.”

ImmunityBio, Inc. engaged Deloitte & Touche LLP as its auditor.

“On March 13, 2025, the Audit Committee approved the engagement of Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to Deloitte's customary client acceptance procedures.”

ImmunityBio, Inc. dismissed Ernst & Young LLP as its auditor.

“On March 13, 2025, the Audit Committee of the Board of Directors (the "Audit Committee") of ImmunityBio, Inc. (the "Company"), approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm.”

John Owen Brennan resigned as Director at ImmunityBio, Inc..

“On February 7, 2025, John Owen Brennan notified the Secretary of ImmunityBio, Inc., a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he served, effective as of February 7, 2025.”

ImmunityBio, Inc.: Board approved a new Code of Business Conduct and Ethics, replacing the prior Code of Global Business Conduct and Ethics, with updated and enhanced provisions including policies on fair dealing and healthcare law compliance (effective 2024-02-22).

“On February 22, 2024, the Board of Directors (the “Board”) of the Company approved a Code of Business Conduct and Ethics to replace the Company’s prior Code of Global Business Conduct and Ethics (each acting as the Company’s “Code of Ethics”).”

ImmunityBio, Inc. entered into Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers valued at $200.0 million (effective 2023-12-29).

“On December 29, 2023 (the “Closing Date”), ImmunityBio, Inc. (the “Company”), entered into a Revenue Interest Purchase Agreement (the “RIPA”) with Infinity SA LLC (the “Purchaser Agent”), an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (each, a “Purchaser”, and collectively, the “Purchasers”). Pursuant to the RIPA, the Purchasers acquired certain revenue interests (the “Revenue Interests”) from the Company for a gross purchase price of $200.0 million (the “First Payment”) paid at closing.”

ImmunityBio, Inc. amended a notes offering with Nant Capital, LLC valued at approximately $535 million (effective 2023-09-11).

“Also on September 11, 2023, the Company and Nant Capital entered into a series of letter agreements pursuant to which the maturity dates of certain existing promissory notes with an aggregate principal amount of approximately $535 million entered into between the Company and Nant Capital were each extended from December 31, 2023 to December 31, 2024.”

ImmunityBio, Inc. entered into Stock Purchase Agreement with Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC valued at approximately $270 million in aggregate principal amount (effective 2023-09-11).

“Also on September 11, 2023, the Company, the Company’s wholly-owned subsidiary NantCell, Inc., Nant Capital, NantMobile, LLC (“NantMobile”) and NantCancerStemCell, LLC (“NCSC” and together with Nant Capital and NantMobile, the “Purchasers”), entered into a Stock Purchase Agreement (the “SPA”) pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the “Notes,” representing approximately $270 million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936 shares of Common Stock.”

ImmunityBio, Inc. entered into $200.0 million Convertible Promissory Note with Nant Capital, LLC valued at $200.0 million (effective 2023-09-11).

“On September 11, 2023, ImmunityBio, Inc. (the “Company”) executed a $200.0 million convertible promissory note with Nant Capital, LLC (“Nant Capital” or the “Investor”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.”

ImmunityBio, Inc. entered into placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”) (effective 2023-07-20).

“On July 20, 2023, the Company also entered into a placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”).”

ImmunityBio, Inc. entered into stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) valued at approximately $40.0 million (effective 2023-07-20).

“On July 20, 2023, ImmunityBio, Inc. (the “Company”) entered into a stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) for the purchase and sale of 14,569,296 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase an additional 14,569,296 shares of Common Stock at an exercise price of $3.2946 per share, for a purchase price of $2.7455 per share and accompanying warrant, generating gross proceeds from the offering of approximately $40.0 million before deducting placement agent fees and other estimated offering expenses (the “Offering”).”

ImmunityBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.

“Votes “For” Votes “Against” Abstentions “Broker Non-Votes” 374,132,354 270,094 278,602 —”

ImmunityBio, Inc. shareholders approved Election of Nine Directors at the 2023-06-13 meeting.

“Nominee Votes “For” Votes “Withheld” “Broker Non-Votes” Patrick Soon-Shiong, M.D. 334,538,179 6,075,920 34,066,951 Cheryl L. Cohen 339,932,285 681,814 34,066,951 Richard Adcock 339,531,860 1,082,239 34,066,951 Michael D. Blaszyk 339,884,168 729,931 34,066,951 John Owen Brennan 337,964,499 2,649,600 34,066,951 Wesley Clark 338,703,037 1,911,062 34,066,951 Linda Maxwell, M.D. 340,016,716 597,383 34,066,951 Christobel Selecky 339,831,897 782,202 34,066,951 Barry J. Simon, M.D. 337,635,450 2,978,649 34,066,951”

ImmunityBio, Inc. incurred loan of $30.0 million with Nant Capital, LLC at Term SOFR plus 8.0% per annum maturing December 31, 2023.

“on June 13, 2023, the Company executed a $30.0 million promissory note with Nant Capital, LLC”

ImmunityBio, Inc. entered into $30.0 million convertible promissory note with Nant Capital, LLC valued at $30.0 million (effective 2023-03-31).

“On March 31, 2023, ImmunityBio, Inc. (the “Company”) executed a $30.0 million convertible promissory note with Nant Capital, LLC”

ImmunityBio, Inc. entered into Placement Agency Agreement with Jefferies LLC (effective 2023-02-15).

“On February 15, 2023, the Company also entered into a placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”). Pursuant to the terms of the PAA, the Placement Agent has agreed to serve as our exclusive Placement Agent on a reasonable best efforts basis to arrange for the sale of the securities described above and the Company has agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds generated from the sale of such securities, less certain Company expenses to be reimbursed by the Placement Agent.”

ImmunityBio, Inc. entered into Stock Purchase Agreement with certain institutional investors valued at approximately $50.0 million (effective 2023-02-15).

“On February 15, 2023, ImmunityBio, Inc. (the “Company”) entered into a stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) for the purchase and sale of 14,072,615 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase an additional 14,072,615 shares of Common Stock at an exercise price of $4.2636 per share, for a purchase price of $3.5530 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0 million before deducting placement agent fees and other estimated offering expenses.”

ImmunityBio, Inc. incurred loan of $50.0 million with Nant Capital, LLC at Term SOFR plus 8.0% per annum maturing December 31, 2023.

“On December 12, 2022, the Company executed a $50.0 million promissory note with Nant Capital, LLC”

ImmunityBio, Inc. entered into $50.0 million promissory note with Nant Capital, LLC valued at $50.0 million (effective 2022-12-12).

“On December 12, 2022, the Company executed a $50.0 million promissory note with Nant Capital, LLC (“Nant Capital”), an entity affiliated with Dr. Patrick Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer.”

ImmunityBio, Inc. entered into the “PAA” with Piper Sandler & Co. valued at cash fee equal to 6.0% of the gross proceeds (effective 2022-12-12).

“On December 12, 2022, the Company also entered into a placement agency agreement (the “PAA”) with Piper Sandler & Co. (the “Placement Agent”).”

ImmunityBio, Inc. entered into the “SPA” with an institutional investor valued at $50.0 million (effective 2022-12-12).

“On December 12, 2022, ImmunityBio, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “Investor”) for the purchase and sale in a registered direct offering of 9,090,909 shares of the Company’s common stock and warrants to purchase an additional 9,090,909 shares at an exercise price of $6.60 per share for a purchase price of $5.50 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0 million before deducting placement agent fees and other estimated offering expenses.”

Patrick Soon-Shiong was appointed as Global Chief Scientific and Medical Officer at ImmunityBio, Inc..

“appointed Patrick Soon-Shiong, M.D., as Global Chief Scientific and Medical Officer of the Company, a newly created executive position, effective immediately.”